The estimated economic value of the welfare loss due to prostate cancer pain in a defined population

Acta Oncologica

Volumn 43, Issue 3, 2004, Pages 290-296

  Sennfält, Karin ^a   Carlsson, Per ^a   Sandblom, Gabriel ^b   Varenhorst, Eberhard ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PAIN; CANCER REGISTRY; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; SOCIOECONOMICS; WELFARE;

COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; MALE; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; PAIN; PAIN MEASUREMENT; PROSTATIC NEOPLASMS; SWEDEN; TIME FACTORS;

EID: 1942511857     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410028411     Document Type: Article

References (28)

1. National Board of Health and Welfare. www.sos.se/epc/fs/ index.htm (accessed 4 August 2003).
2. Swedish Cancer Society, National Board of Health and Welfare. Cancer in figures 2001 (in Swedish). Stockholm: SCS; 2001.
3. Borre M, Nerstrom B, Overgaard J. The dilemma of prostate cancer. Acta Oncol 1997; 36(7): 681-7.
4. National Board of Health and Welfare. Cancer incidence in Sweden 1999 Stockholm: Health and Diseases; 2001. p. 4.
5. Greenwald H, Bonica J, Bergner M. The prevalence of pain in four cancers. Cancer 1987; 60: 2563-9.
6. Cleeland C, Gonin R, Hatfield A, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592-6.
7. Jonler M, Nielsen O, Wolf H. Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology 1998; 52(6): 1055-62.
8. Lubeck D, Litwin M, Henning J, Stoddard M, Flanders S, Carrol R. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaP-SURE. Urology 1999; 53(1): 180-6.
9. Portenoy R, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695-700.
10. Wang X, Cleeland C, Mendoza T, et al. The effects of pain severity on health-related quality of life. Cancer 1999; 86: 1848-55.
11. Krupski T, Petroni G, Bissonette E, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000; 55(5): 736-42.
12. Larue F, Colleau S, Brasseur L, Cleeland C. Multicentre study of cancer pain and its treatment in France. Br Med J 1995; 310: 1034-7.
13. Cleary P, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995; 4: 207-20.
14. Sandblom G, Carlsson P, Sigsjö P, Varenhorst E. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001; 85(4): 497-503.
15. Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden an assessment of data reproducibility in the South-East region prostate cancer register. Scand J Urol Nephrol 2003; 37(2): 112-9.
16. The EuroQol Group. EuroQol - a new facility for measurement of health related quality of life. Health Policy 1990; 16: 199-208.
17. EuroQol group. EQ-5D. User guide. A measure of health-related quality of life. Rotterdam: EuroQol Business Management; 1996.
18. Brooks R, Jendteg S, Lindgren B, Persson U, Björk S. EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy 1991; 18: 37-48.
19. Chapman R, Stone P, Sandberg E, Bell C, Neuman P. A comprehensive league table of cost-utility ratios and a sub-table of 'panel-worthy' studies. Med Decis Making 2000; 20(4): 451-67.
20. Kobelt G, Jönsson L, Henriksson F, Fredrikson S, Jönsson B. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 2000; 16(3): 768-80.
21. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Economics 1998; 7: 1-7.
22. Hirth R, Chernew M, Miller E, Fendrick A, Weissert W. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-42.
23. Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Economics 1998; 7: S79-92.
24. Gyrd-Hansen D. Willingness to pay for a QALY. Health Economics 2003; 12: 1049-60.
25. Neighbors D, Bell T, Wilson J, Dodd S. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. Pain Symptom Manage 2001; 21(2): 129-43.
26. Sennfält K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E. Technological changes in the management of prostate cancer result in increased healthcare costs. Scand J Urol Nephrol 2003; 37: 226-31.
27. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-84.
28. George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia 1991-96. Centre for Health Program Evaluation. Working Paper 1999, p. 89.